TRVI
Trevi Therapeutics, Inc.
$19.50
+1.55 (+8.64%)
At close · Jul 7
Market Cap
$2.73B
Shares
141,979,708
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$19.50
Open$17.99
Day$17.91–20.15
52W$5.78–20.15
Avg vol 30d2.0M
Short int14.4M · 10.1% float · 14.8d
Short vol69%
Last earningsApr 17, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 5
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+58%
above
Price vs 50-day avg
+29%
above
RSI (14)
74
overbought
MACD trend
Positive
52-week position
95%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+46%
trailing
6-month return
+73%
trailing
YTD return
+56%
this year
Relative strength
+65%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $15 › 200d $12 — 50d above 200d
Institutional flow
Accumulating
6 of 200 funds reported for Jun 30 · net +1.5M sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.11% of float · ▲ +5.7% MoM · 14.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
200 holders — near 3-yr high, broad support
Squeeze score
78
high risk · 0–100
Fundamentals
EPS growth
+32%
Y/Y
Free cash flow
$-42.1M
Balance sheet
$18.9M
net cash
Quant / Vol
risk profile
Volatility
62%
annualized · 1-yr
Max drawdown
−30%
past year
ATR
4.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+58%
Bullish
Price vs 50-day avg
+29%
Bullish
RSI (14)
74
Bearish
MACD trend
Positive
Bullish
52-week position
95%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $15 › 200d $12 — 50d above 200d
Institutional flow
Accumulating
6 of 200 funds reported for Jun 30 · net +1.5M sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.11% of float · ▲ +5.7% MoM · 14.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
200 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $6
Now $20 · 95%
52-wk high $20
vs 200-day avg +58%
vs 50-day avg +29%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TRVI
this stock
Trevi Therapeutics, Inc.
|
$2.73B | +55.8% | — | — | 10.1% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TRVI | +4.7% | +46.3% | +72.7% | +4.6% | +55.8% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +3.8% | +44.9% | +65.2% | +4.4% | +46.1% |